A Study of Lemborexant in Chinese Participants With Insomnia Disorder
Status:
Recruiting
Trial end date:
2022-11-11
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to confirm using polysomnography (PSG) that lemborexant
10 milligram (mg) is superior to placebo on objective sleep onset as assessed by latency to
persistent sleep (LPS) during the last 2 nights of 1 month of treatment in participants with
insomnia disorder.